Arkolith/Insider Trading/PHIO/Form 4

Bitterman Robert J

Chairman, Pres & CEO, DirectorPhio Pharmaceuticals Corp. (PHIO) · full profile →Form 4 · filed May 23, 2025
Net Buying
Open-Market Buys
$7K
Open-Market Sells
$0
Net Open-Market Flow
$7K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 22, 2025Buy(P)1K$1.78$2K24K
May 21, 2025Buy(P)3K$1.77$5K22K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-25-010155) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML